Shanghai Changzheng Hospital

This early-stage study is testing whether adding an experimental oral drug called LC-K76 to standard hormone therapy helps control metastatic prostate cancer that still responds to hormones. It will involve about 40 men who have not had prior cancer treatment, focusing primarily …

This early study is testing the safety and initial effectiveness of a new oral drug called LC-K76 when given alongside an immunotherapy drug (Tislelizumab) in men with advanced prostate cancer that has spread to the bones and is no longer responding to standard hormone therapies …

This study is testing a new blood test that uses advanced quantum sensors and artificial intelligence to detect prostate cancer early. It aims to help doctors diagnose cancer more accurately without needing as many invasive biopsies. The test will be studied in about 1,100 men wh…